120 related articles for article (PubMed ID: 36733110)
21. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Parisi A; Porzio G; Cannita K; Venditti O; Avallone A; Filippi R; Salvatore L; Tortora G; Ribelli M; Nigro O; Gelsomino F; Spallanzani A; Zurlo V; Leo S; Dell'Aquila E; Claudia F; Lombardi P; Keränen SR; Aimar G; Depetris I; Giampieri R; Morelli C; De Tursi M; Tinari N; Di Pietro FR; De Galitiis F; Zanaletti N; Troiani T; Vitale P; Garajova I; Ghidini M; Spinelli GP; Zoratto F; Roberto M; Ierino D; Petrillo A; D'Orazio C; Ficorella C; Cortellini A
Clin Colorectal Cancer; 2021 Dec; 20(4):318-325. PubMed ID: 34380594
[TBL] [Abstract][Full Text] [Related]
22. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
24. [Three Cases of Unresectable Colorectal Cancer Curatively Resected after Effective Chemotherapy].
Kinoshita H; Noda E; Mori T; Hasegawa T; Teraoka H; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2019 Mar; 46(3):567-569. PubMed ID: 30914616
[TBL] [Abstract][Full Text] [Related]
25. [Systemic chemotherapy and surgery for recurrent metachronous liver metastases with peritoneal dissemination from triple colon cancers-a case report].
Kato T; Noda H; Watanabe F; Kakizawa N; Toyama N; Rikiyama T
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2615-7. PubMed ID: 25596059
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
Patel KK; Stein S; Lacy J; O'Hara M; Huntington SF
JAMA Netw Open; 2021 Jan; 4(1):e2033441. PubMed ID: 33433598
[TBL] [Abstract][Full Text] [Related]
27. [New Treatment Strategies for BRAF Mutation-Positive Colorectal Cancer].
Kawakami H; Ogata S
Gan To Kagaku Ryoho; 2021 Jun; 48(6):787-795. PubMed ID: 34139726
[TBL] [Abstract][Full Text] [Related]
28. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Yoon HH; Tougeron D; Shi Q; Alberts SR; Mahoney MR; Nelson GD; Nair SG; Thibodeau SN; Goldberg RM; Sargent DJ; Sinicrope FA;
Clin Cancer Res; 2014 Jun; 20(11):3033-43. PubMed ID: 24687927
[TBL] [Abstract][Full Text] [Related]
29. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
[TBL] [Abstract][Full Text] [Related]
30. [BRAF V600E-mutant colorectal cancers: Where are we?].
Lièvre A; de la Fouchardière C; Samalin E; Benoist S; Phelip JM; André T; Lledo G
Bull Cancer; 2020 Sep; 107(9):881-895. PubMed ID: 32674932
[TBL] [Abstract][Full Text] [Related]
31. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
32. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Ogino S; Liao X; Imamura Y; Yamauchi M; McCleary NJ; Ng K; Niedzwiecki D; Saltz LB; Mayer RJ; Whittom R; Hantel A; Benson AB; Mowat RB; Spiegelman D; Goldberg RM; Bertagnolli MM; Meyerhardt JA; Fuchs CS;
J Natl Cancer Inst; 2013 Dec; 105(23):1789-98. PubMed ID: 24231454
[TBL] [Abstract][Full Text] [Related]
33. [New drug approval: Encorafenib-metastatic colorectal cancers with BRAF V600E mutation after systemic chemotherapy].
Boilève A; Samalin E
Bull Cancer; 2020 Nov; 107(11):1086-1088. PubMed ID: 33046237
[No Abstract] [Full Text] [Related]
34. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.
Bruzzi M; Auclin E; Lo Dico R; Voron T; Karoui M; Espin E; Cianchi F; Weitz J; Buggenhout A; Malafosse R; Denimal F; Le Malicot K; Vernerey D; Douard R; Emile JF; Lepage C; Laurent-Puig P; Taieb J
Ann Surg Oncol; 2019 Oct; 26(11):3561-3567. PubMed ID: 31209667
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
36. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
Hutchins G; Southward K; Handley K; Magill L; Beaumont C; Stahlschmidt J; Richman S; Chambers P; Seymour M; Kerr D; Gray R; Quirke P
J Clin Oncol; 2011 Apr; 29(10):1261-70. PubMed ID: 21383284
[TBL] [Abstract][Full Text] [Related]
37. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.
Brandi G; Tavolari S; De Rosa F; Di Girolamo S; Agostini V; Barbera MA; Frega G; Biasco G
PLoS One; 2012; 7(7):e41347. PubMed ID: 22911782
[TBL] [Abstract][Full Text] [Related]
38. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
Sasaki Y; Hamaguchi T; Yamada Y; Takahashi N; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Nagai Y; Taniguchi H; Boku N; Ushijima T; Shimada Y
Asian Pac J Cancer Prev; 2016; 17(2):539-43. PubMed ID: 26925640
[TBL] [Abstract][Full Text] [Related]
39. [Anti-EGFR Antibody Combination Chemotherapy Was Effective against Locally Advanced Ascending Colon Cancer as Well as a Recurrent Lesion - A Case Report].
Yamada Y; Yokomizo H; Yano Y; Okayama S; Satake M; Ida A; Usui T; Yamaguchi K; Shiozawa S; Yoshimatsu K; Shimakawa T; Katsube T; Naritaka Y; Kato H
Gan To Kagaku Ryoho; 2017 Oct; 44(10):947-949. PubMed ID: 29066705
[TBL] [Abstract][Full Text] [Related]
40. [Estimation of peritoneal dissemination in patients with unresectable advanced or recurrent colorectal cancer who underwent curative resection after combination chemotherapy].
Mizota S; Ikeda S; Yamauchi M; Imaoka Y; Mashima H; Okimoto S; Takakura Y; Noma M; Ohara M; Oishi K; Kohashi T; Fudaba Y; Ishimoto T; Matsugu Y; Nakahara H; Urushihara T; Shinozaki K; Itamoto T
Gan To Kagaku Ryoho; 2014 May; 41(5):595-600. PubMed ID: 24917004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
